We have observed
16 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 12, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS
HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS
TREATMENT OF PROLIFERATIVE DISORDERS WITH A CHEMILUMINESCENT AGENT
DEVICE FOR DISPLAYING FLOWER BOUQUETS OR POTTED PLANTS
METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES
METHOD AND APPARATUS FOR PRODUCING COMPOSITE STRUCTURE
Mesenchymal stem cells for the treatment of CNS diseases
NUCLEIC ACID CONSTRUCT FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
TYMPANIC MEMBRANE REPAIR DEVICE
GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
VIRAL INHIBITOR COMPOSITION FOR IN VIVO THERAPEUTIC USE
THIXOTROPIC BIOLOGICAL ADHESIVE FOR USE IN INTERNAL BODY CAVITIES
METHOD FOR ISOTOPIC MEASUREMENT BY ICPMS
METHOD FOR REINFORCING AN ALLOY BY PLASMA-NITRIDING